Cabaletta Bio, Inc. (CABA) Grows With T Cell Therapy Focus

Cabaletta Bio, Inc. (CABA) is a clinical-stage biotechnology company developing engineered T cell therapies to treat autoimmune diseases. Its lead programs target diseases like pemphigus vulgaris and lupus by selectively eliminating disease-causing B cells. Using its advanced CARTA platform, Cabaletta aims to deliver precise, durable treatments. The company’s growth is fueled by clinical progress, strong trial data, and rising interest in cell-based therapies for chronic immune disorders.

On the chart, a confirmation bar with rising volume highlights bullish sentiment. The price has entered the momentum zone after breaking above the .236 Fibonacci level. A trailing stop can be set just below this Fibonacci line using the Fibonacci snap tool, helping traders protect gains while leaving room for continued upside potential.